STEMCELL Launches Novel Cell-Engineering CellPore™ Transfection System
01 August 2024 - 2:00AM
Business Wire
STEMCELL Technologies has commercially launched the CellPore™
Transfection System, providing a groundbreaking new technology with
the potential to advance cell engineering research and the
development of novel cell therapies to cure diseases.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240731230715/en/
STEMCELL Technologies has commercially
launched the CellPore™ Transfection System, providing a
groundbreaking new technology with the potential to advance cell
engineering research and the development of novel cell therapies to
cure diseases. (Pictured: CellPore™ Transfection System)
The CellPore™ Transfection System represents a substantial leap
forward for cell engineering researchers, offering a novel
method—known as mechanoporation—for cargo delivery into mammalian
cells. Unlike traditional electroporation techniques, the CellPore™
Transfection System squeezes cells to create temporary pores in the
cell membrane through which the cargo is introduced.
“The launch of the CellPore™ Transfection System, together with
our various cell isolation and culture product portfolios, will
equip the research community with the technology to advance the
field of cell engineering,” said Dr. Allen Eaves, President and
CEO, STEMCELL. “This product offering has solidified STEMCELL's
leadership in cell delivery using mechanoporation technology, with
promising implications for both research and clinical
applications.”
In 2022, STEMCELL announced a collaboration with SQZ
Biotechnologies, followed by the acquisition of substantially all
of the company’s assets in February 2024, including its entire
portfolio of over 400 patents and trademarks, and other
intellectual property such as copyrights and trade secrets.
STEMCELL then successfully leveraged SQZ’s Cell Squeeze® technology
and intellectual property to commercialize and launch the CellPore™
Transfection System.
The CellPore™ platform, designed for Research Use Only
applications, includes the benchtop CellPore™ Transfection System
and the CellPore™ Transfection Kit 300 that features a specialized
reagent kit and single-use delivery cartridges. This
state-of-the-art system leverages a mechanism of rapid, controlled
cell deformation within microfluidic channels to create transient
pores in the plasma membrane. This facilitates the efficient and
gentle delivery of target molecules, such as small molecules,
nucleic acids, proteins, and gene editing complexes, into human
cells. This method ensures minimal cell perturbation and maintains
high cell quality, crucial for advancing biological research and
the development of novel cell and gene-based therapies.
“As a company of Scientists Helping Scientists, we are excited
about the positive impacts this technology will have on the life
sciences sector and specifically on critical research into cancer
and other devastating diseases,” concluded Dr. Eaves.
About STEMCELL Technologies STEMCELL Technologies
supports life sciences research with more than 2,500 specialized
reagents, tools, and services. STEMCELL offers high-quality cell
culture media, cell separation technologies, instruments, accessory
products, educational resources, and contract assay services that
are used by scientists performing stem cell, immunology, cancer,
regenerative medicine, and cellular therapy research globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240731230715/en/
For more information and to arrange an interview, contact:
Ryan-Sang Lee Director, Corporate Communications and Media
Relations, STEMCELL Technologies public.relations@stemcell.com